APA
Pérez de Isla L., Ray K. K., Watts G. F., Santos R. D., Alonso R., Muñiz-Grijalvo O., Diaz-Diaz J. L., Badimon L., Catapano A. L. & Mata P. (20200709). Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. : Atherosclerosis.
Chicago
Pérez de Isla Leopoldo, Ray Kausik K, Watts Gerald F, Santos Raul D, Alonso Rodrigo, Muñiz-Grijalvo Ovidio, Diaz-Diaz Jose Luis, Badimon Lina, Catapano Alberico L and Mata Pedro. 20200709. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. : Atherosclerosis.
Harvard
Pérez de Isla L., Ray K. K., Watts G. F., Santos R. D., Alonso R., Muñiz-Grijalvo O., Diaz-Diaz J. L., Badimon L., Catapano A. L. and Mata P. (20200709). Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. : Atherosclerosis.
MLA
Pérez de Isla Leopoldo, Ray Kausik K, Watts Gerald F, Santos Raul D, Alonso Rodrigo, Muñiz-Grijalvo Ovidio, Diaz-Diaz Jose Luis, Badimon Lina, Catapano Alberico L and Mata Pedro. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. : Atherosclerosis. 20200709.